StreetInsider.com News Articles

Form 6-K Enlivex Ltd. For: Jul 30

Thu, 30 Jul 2026 08:02:00 -0400

si-local-file:///var/storage/secattach/20260730/26839277.html

Form 6-K Enlivex Ltd. For: Jul 30

Thu, 30 Jul 2026 08:02:00 -0400

si-local-file:///var/storage/secattach/20260730/26839277.html

Form 6-K Enlivex Ltd. For: Jul 29

Wed, 29 Jul 2026 08:02:00 -0400

si-local-file:///var/storage/secattach/20260729/26830972.html

Form 6-K Enlivex Ltd. For: Jul 29

Wed, 29 Jul 2026 08:02:00 -0400

si-local-file:///var/storage/secattach/20260729/26830972.html

Form 6-K Enlivex Ltd. For: Jul 28

Tue, 28 Jul 2026 16:40:00 -0400

si-local-file:///var/storage/secattach/20260728/26827786.html

Form 6-K Enlivex Ltd. For: Jul 28

Tue, 28 Jul 2026 16:40:00 -0400

si-local-file:///var/storage/secattach/20260728/26827786.html

Enlivex plans $400M private placement tied to crypto tokens

Tue, 28 Jul 2026 08:02:48 -0400

Enlivex Ltd. (NASDAQ: ENLV) has entered into a securities purchase agreement with a single institutional investor for a private placement of $400 million in ordinary shares, according to a company statement.

Shares are priced at $5.00 each for subscriptions funded in U.S. dollars, USDT, or USD Coin, and at $6.00 per share for subscriptions funded in RAIN tokens. The $5.00 price represents a 17.4% premium and the $6.00 price a 40.8% premium to the closing share price on July 27, 2026. The investor has elected to fund the purchase using RAIN tokens, though that election may be changed before closing.

The agreement

Enlivex plans $400M private placement tied to crypto tokens

Tue, 28 Jul 2026 08:02:48 -0400

The agreement

Form 6-K Enlivex Ltd. For: Jul 28

Tue, 28 Jul 2026 08:02:00 -0400

si-local-file:///var/storage/secattach/20260728/26822797.html

Form 6-K Enlivex Ltd. For: Jul 28

Tue, 28 Jul 2026 08:02:00 -0400

si-local-file:///var/storage/secattach/20260728/26822797.html

Form 6-K Enlivex Ltd. For: Jul 20

Mon, 20 Jul 2026 08:02:00 -0400

si-local-file:///var/storage/secattach/20260720/26787346.html

Form 6-K Enlivex Ltd. For: Jul 20

Mon, 20 Jul 2026 08:02:00 -0400

si-local-file:///var/storage/secattach/20260720/26787346.html

FDA grants RMAT designation to Enlivex's Allocetra for knee OA

Mon, 13 Jul 2026 08:01:06 -0400

Enlivex Ltd. (NASDAQ: ENLV) announced that the U.S. Food and Drug Administration has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its clinical-stage immunotherapy Allocetra™ for the treatment of age-related symptomatic knee osteoarthritis in patients aged 64 and older.

The FDA based the designation on clinical evidence from a completed Phase I/IIa trial, in which patients with primary age-related knee osteoarthritis treated with Allocetra™ showed statistically significant and clinically meaningful improvements in knee pain and physical function compared with placebo, with efficacy that was durable through at least six months.

RMAT designation makes a therapy potentially eligible for accelerated approval, priority review,

FDA grants RMAT designation to Enlivex's Allocetra for knee OA

Mon, 13 Jul 2026 08:01:06 -0400

RMAT designation makes a therapy potentially eligible for accelerated approval, priority review,

Enlivex Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Allocetra™ in Age-Related Knee Osteoarthritis